Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
Lung Cancer, 05/08/2012
Spigel DR et al. – This phase II trial provides support for further study of sunitinib maintenance therapy following platinum–doublet chemotherapy in patients with extensive–stage (ES)–small–cell lung cancer (SCLC). The 1year overall survival (OS) of 54% is encouraging, and a randomized trial would be appropriate to assess sunitinib's impact following chemotherapy.